- Home
- ELEV vs ENLV Comparison
ELEV vs ENLV Comparison
Compare ELEV & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- ENLV
- Stock Information
- Founded
- ELEV 2019
- ENLV 2005
- Country
- ELEV United States
- ENLV Israel
- Employees
- ELEV N/A
- ENLV N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- ENLV Health Care
- Exchange
- ELEV Nasdaq
- ENLV Nasdaq
- Market Cap
- ELEV 22.6M
- ENLV 23.7M
- IPO Year
- ELEV 2021
- ENLV 1995
- Fundamental
- Price
- ELEV $0.38
- ENLV $1.23
- Analyst Decision
- ELEV Hold
- ENLV Strong Buy
- Analyst Count
- ELEV 6
- ENLV 2
- Target Price
- ELEV $1.77
- ENLV $10.00
- AVG Volume (30 Days)
- ELEV 938.5K
- ENLV 129.6K
- Earning Date
- ELEV 08-05-2025
- ENLV 08-29-2025
- Dividend Yield
- ELEV N/A
- ENLV N/A
- EPS Growth
- ELEV N/A
- ENLV N/A
- EPS
- ELEV N/A
- ENLV N/A
- Revenue
- ELEV N/A
- ENLV N/A
- Revenue This Year
- ELEV N/A
- ENLV N/A
- Revenue Next Year
- ELEV N/A
- ENLV N/A
- P/E Ratio
- ELEV N/A
- ENLV N/A
- Revenue Growth
- ELEV N/A
- ENLV N/A
- 52 Week Low
- ELEV $0.22
- ENLV $0.81
- 52 Week High
- ELEV $3.28
- ENLV $1.76
- Technical
- Relative Strength Index (RSI)
- ELEV 54.73
- ENLV 58.80
- Support Level
- ELEV $0.36
- ENLV $1.14
- Resistance Level
- ELEV $0.38
- ENLV $1.38
- Average True Range (ATR)
- ELEV 0.01
- ENLV 0.10
- MACD
- ELEV -0.00
- ENLV 0.01
- Stochastic Oscillator
- ELEV 53.93
- ENLV 44.44
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.